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Precipitation and flocculation are optimal unit operations for continuous capture of proteins from culture 
supernatant. Precipitation and flocculation can be 
operated in a real continuous manner. The methods can 
be combined and after this capture step the precipitate 
can be stored as a concentrated solution or even as a 
precipitate. We have developed several precipitation/ 
flocculation protocols for capture of antibodies from 
culture supernatant. These include the combinations of 
CaCl2 flocculation with either cold ethanol precipitation or 
PEG precipitation and octanoic acid precipitation with 
PEG precipitation. The precipitation conditions have been 
screened in microtiter plates or in case of cold ethanol 
precipitation in small scale reactors. For cold ethanol 
precipitation a combination with CaCl2 flocculation is best 
suited. In the first step the high molecular mass impurities 
can be removed by flocculation with CaCl2 while in the 
second step the antibody is precipitated by addition of 
ethanol and low molecular mass impurities are removed. 
The whole procedure can be repeated and then final 
polishing can be performed by an anion exchange step in 
flow through mode. Octanoic acid precipitation is also a 
very efficient step but an additional phase can be formed 
which is difficult to remove. In Figure 1 a bench top reactor 
for cold ethanol precipitation is depicted. The rector 
consists of two sections (Figure 1). First a concurrent 
cooling is installed to ensure a constant cooling rate while 
ethanol is added to the culture supernatant or pre-treated 
supernatant. In the second section a countercurrent 
cooling is installed to keep the reactors at the requested 
temperature. The industry standard for antibody capture is 
protein A affinity chromatography. Thus the properties of 
the antibody after cold ethanol precipitation have been 
compared to protein A purified material. No significant 
difference could be observed (Figure 2) in either 
composition or structure. Further purification has been 
tested by anion-exchange monoliths in order to remove 
further host cell proteins. The different protocols will be 
compared to other standard platforms for antibody 
purification. The possibilities to integrate in-process control 
and maintenance of steady state will be discussed. The 
economics of such a process will be discussed for the 
different scenarios of clinical phase manufacturing and how strategies can be developed when antibodies 
become commodities or when oral delivery becomes reality. Next steps will be shown how to scale up such a 
process. 
Figure 1 – Benchtop continuous reactor for cold 
ethanol precipitation of antibodies; top left: bench 
top tubular reactor, top right: temperature-profile at 
five different section in the reactor, bottom: 
schematic drawing of the reactor  
Figure 2 – Comparison of protein A purified antibody 
with antibody purified by CE: (A) ATR-FTIR,  (B) 
analytical ion- exchange chromatography with linear 
pH- gradient, (C) isoelectric focusing (B) affinity to 
FcIII receptor measured by Biacore.  
